time to buy, page-17

Yes well, I hear what the company is saying but am yet to hear about any real solid data using their pylomers. I still think their potenital has been rather pumped. Let's see what the real results are when their phylomers actually go into clinical trial....if they ever do. The bottom line is, this approach does have potential and may actually yield some good findings but the data to date is still very tenuous and the company is basing itself on the potential rather than the fact. If it was fact don't you think they would have been bought out by now! I hold on the fact that the ramping is sending the share price higher. Face it, in this game (spec share trading) reality means very little, it's all about perception.